Expert Interview
With the recent delay on TLando's approval, a conversation about the market potential if approved.
Ticker(s): LPCN, Clarus TherapeuticsA physician who is a high prescriber or testosterone products to patients and has followed the TLando story over the past few years.
Do you think TLando will be approved by the FDA in the coming weeks?
Added By: joe_mccannIf TLando is approved, what % of your patients currently on testosterone replacement therapy would you switch to TLando?
Added By: joe_mccannIs there a group of patients who currently should be receiving testosterone therapy, but do not? Would TLando be a good option for them?
Added By: joe_mccannDo you think the TMax excursion issue was likely resolved in this filing?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
